

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## JOINN LABORATORIES (CHINA) CO., LTD.

### 北京昭衍新藥研究中心股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6127)

## SUPPLEMENTAL ANNOUNCEMENT FURTHER INFORMATION IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Reference is made to the announcement of JOINN Laboratories (China) Co., Ltd. (北京昭衍新藥研究中心股份有限公司) (the "Company") for the year ended 31 December 2022 (the "2022 Annual Report"). Unless otherwise defined, capitalized and underlined terms shall have the meanings as defined in the 2022 Annual Report.

### PRE-IPO SHARE OPTION AND RESTRICTED AWARD SCHEMES

In addition to the information disclosed in the aforesaid headed "PRE-IPO SHARE OPTION AND RESTRICTED AWARD SCHEMES" in the Report for December 2022, as set out in the 2022 Annual Report, the Company is hereby providing the following information in relation to the 2019 Share Option and Restricted Share Award Scheme and the 2020 Share Option and Restricted Share Award Scheme in accordance with Rule 17.09(3) of the Listing Rules.

The table below sets out the details of the exercise of the restricted share award scheme for the year ended 31 December 2022 in relation to the 2019 Share Option and Restricted Share Award Scheme and the 2020 Share Option and Restricted Share Award Scheme as follows:

### THE 2019 SHARE OPTION AND RESTRICTED SHARE AWARD SCHEME

Date of the 2022 Annual Report

30 March 2023

#### Options

The number of restricted share awards exercised: 40,926

The exercise price of the restricted share awards exercised: 0.008%

**Date of the 2022 Annual Report**

**30 March 2023**

**RSUs**

The number of RSUs available: 3,293

The percentage of restricted share available: 0.0006%

**THE 2020 SHARE OPTION SCHEME**

**Date of the 2022 Annual Report**

**30 March 2023**

**Options**

The number of options available: 1,420,020

The percentage of restricted share available: 0.27%

**POST-IPO SHARE INCENTIVE SCHEME AND THE STOCK OWNERSHIP PLAN**

In addition to the adopted and amended POST-IPO RESTRICTED SHARE INCENTIVE SCHEME AND THE STOCK OWNERSHIP PLAN, the Board of Directors of the 2022 Annual Report, the Company adopted the defined share award scheme, referred to as the 2021 Restricted Share Incentive Scheme, in accordance with Rule 17.07(1)(c) and Rule 17.07(2) of the Listing Rules.

The following table (referred to as the "List of Grantees") sets out the details of the LIST OF GRANTEES UNDER THE POST-IPO SHARE OPTION AND RESTRICTED SHARE AWARD SCHEMES, the Board of Directors: (i) considers the share award to be in the best interests of the Company; (ii) considers the share award to be in the best interests of the Company; (iii) considers the share award to be in the best interests of the Company; and (iv) considers the share award to be in the best interests of the Company.

**LIST OF GRANTEES UNDER THE POST-IPO SHARE OPTION AND RESTRICTED SHARE AWARD SCHEMES**

The following table sets out the details of the ASAs for the 2021 Restricted Share Incentive Scheme as at 31 December 2022.

| Name of Grantee                        | Exercise Price (RMB/Share) <sup>(4)</sup> | Date of Grant   | Outstanding as at the adoption date (i.e. 19 January 2022) | Grant during the year <sup>(5)(7)</sup> | Exercised during the year <sup>(3)</sup> | Vesting Period and Canceled during the year | Lapsed during the year | Outstanding as at 31 December 2022 <sup>(6)</sup> |
|----------------------------------------|-------------------------------------------|-----------------|------------------------------------------------------------|-----------------------------------------|------------------------------------------|---------------------------------------------|------------------------|---------------------------------------------------|
| Key Executive (b. (e.))<br>(297, (e.)) | 83.97/59.72                               | 28 January 2022 | 0                                                          | 366,300                                 | 0                                        | (Notes 1&2)                                 | 0                      | 512,820                                           |

Notes:

- (1) The balance of restricted RSUs under the 2021 Restricted A Share Incentive Scheme shall be calculated according to the following formula: ( ) a 40% of the balance of Restricted Shares before 29 March 2023 and 28 March 2024; ( ) a 30% of the balance of RSUs before 29 March 2024 and 28 March 2025; and ( ) a 30% of the balance of RSUs before 29 March 2025 and 28 March 2026.
- (2) The term of validity of outstanding RSUs shall not exceed 48 months. And the exercise period of outstanding RSUs shall commence from the date on which such restricted shares are no longer under any lock-ups and shall not exceed the validity period.**
- (3) No RSU shall be exercised during the period.
- (4) The exercise price of the RSUs shall be determined by the Board as of the first trading day of the Company's shares on the Shanghai Stock Exchange on 28 January 2022. The Company shall award 4 billion shares at a price of RMB10.00 per share. For details, please refer to the Company's 2022 Annual Report.
- (5) The balance of RSUs awarded during the period shall be determined by the Board as of the first trading day of the Company's shares on the Shanghai Stock Exchange on 28 January 2022.
- (6) The balance of restricted RSUs as at 31 December 2022 shall be determined according to the following formula: ( ) a 40% of the balance of RSUs as at 31 December 2022.
- (7) The total number of RSUs available for grant under the 2021 Restricted A Share Incentive Scheme was 512,820 and as at 31 December 2022 nil RSU was available for further grant.**
- (8) The closing price of the Shares immediately before the date of grant of RSUs on 28 January 2022 was RMB97.24. The fair value of the awards was RMB12.91.**
- (9) The 2021 Restricted A Share Incentive Scheme was adopted on 19 January 2022. Therefore, there is no awards available for grant as at 1 January 2022.**

The above information is for your reference and does not constitute an offer of securities. The Board of Directors of the Company is not responsible for the accuracy of the information. For more information, please refer to the 2022 Annual Report.

B e f e B a d  
**JOINN Laboratories (China) Co., Ltd.**  
**Feng Yuxia**  
*Chairperson*

Beijing, PRC  
10 April 2023

*As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng, Ms. Sun Yunxia and Dr. Yao Dalin as executive Directors, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-executive Directors.*